Like eClinical Insights, Inc.

closed 11/6/2014 via Company Press Release

ERT, acquired eClinical Insights, Inc.

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights (eCI), an innovative provider of cloud-based clinical trials management software.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target: eClinical Insights, Inc.
eClinical Insights® is a leading-edge provider of cloud-based clinical software that provides clinical research professionals with the strategic visibility to make rapid, data-driven decisions to positively impact the performance and cost of their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/13/2019 via BusinessWire

Saama Technologies, will acquire Comprehend Systems, Inc.

synopsis: Saama Technologies, Inc., the advanced clinical data and analytics company, announced that it has signed a definitive agreement to acquire Comprehend Systems, Inc., a company that provides a suite of cloud applications and consulting services that dramatically improve the clinical trial process.
buyer: Saama Technologies
Saama Technologies is the advanced clinical data and analytics company, unleashing wisdom from data to deliver better actionable business outcomes for the life sciences industry. "
target: Comprehend Systems, Inc.
Comprehend provides a suite of cloud applications and consulting services that dramatically improve the clinical trial process. Their solutions deliver actionable risk and performance insights across studies, systems, sites, and vendors.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/24/2009 via PR Newswire

OmniComm Systems, Inc., purchased EDC Solutions from eResearch Technology, Inc.

synopsis: OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, has acquired the EDC business of eResearchTechnology, Inc., a global provider of technology and services that enable life science industries worldwide to collect, interpret, and distribute cardiac safety and clinical data.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. "
seller: eResearch Technology, Inc.
eResearchTechnology, Inc. (eRT) is a provider of technology-based products and services that enable the pharmaceutical, biotechnological, medical device, and contract resource companies to collect, interpret, and distribute cardiac safety and clinical data more efficiently.
price ($mm)[EV]
$2.02 [$0.87]
rev ($mm)
$6
EBITDA ($mm)
EV / rev
0.1x
EV / EBITDA
closed 7/15/2009 via BusinessWire

Merge Healthcare, acquired etrials, Inc.

synopsis: Merge Healthcare Inc., a leading health IT solutions provider, and etrials Worldwide, Inc., a leading provider of clinical trials software and services, announced the expiration of the exchange offer for the shares of etrials’ common stock by Merge Acquisition Corp. Merge now owns approximately 86% of the outstanding shares of Etrials common stock.
buyer: Merge Healthcare (MRGE:$227.59)
Merge Healthcare Incorporated builds software solutions that automate healthcare data and diagnostic workflow to build a better electronic record of the patient experience. "
target: etrials, Inc.
etrials has earned the loyalty of its healthcare partners by guiding them to simplify and accelerate the processes associated with collecting data in clinical trials. Using innovative technologies and proven business processes, etrials offers the most efficient data management products and services.
price ($mm)[EV]
$21 [$14]
rev ($mm)
$16
EBITDA ($mm)
EV / rev
0.9x
EV / EBITDA
announced 5/30/2019 via BusinessWire

Evidera, will acquire Medimix International

synopsis: Evidera, a business unit of PPD, LLC, and a provider of evidence-based solutions demonstrating the real-world effectiveness and safety of health care products, will acquire Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic and medical device industries.
buyer parent: Carlyle Group
buyer: Evidera
Evidera, a PPD business unit, is a leading provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of health care products. They help biopharmaceutical, biotechnology and medical device companies generate the evidence needed to optimize the market access. "
target: Medimix International
Medimix International specializes in providing business understanding, real-world evidence insights to the pharmaceutical and medical device industries. Medimix’s primary solution, LiveTracker™, is a cloud-based platform that provides real-time monitoring of clients’ particular therapeutic markets.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/7/2014 via PR Newswire

Decision Resources Group, acquired Relay Technology Management

synopsis: Piramal Enterprises' Information Management Subsidiary, Decision Resources Group, one of the world's leading research and advisory firms focusing on high-value healthcare insights and analytics, announced that it acquired Relay Technology Management, a data analytics company focused on the life-sciences industry.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Relay Technology Management
Relay Technology Management is a life sciences business intelligence software provider founded in 2008 with one core belief: that enabling data-driven decision-making via objective, standard asset valuation and trend analytics will lead to increased efficiency in drug development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/15/2013 via Company Press Release

Litéra Corp, purchased AxxiTRIALS from Axxiem Web Solutions

synopsis: Litera has announced the acquisition of AxxiTRIALS from Axxiem Web Solutions. AxxiTRIALS is a leading Clinical Trials Portal solution providing life science companies and clinical research organizations (CROs) with a platform designed to dramatically speed site start-up, patient recruitment, and end-to-end clinical trial operations.
buyer: Litéra Corp
Litéra Corp. engages in developing and marketing content lifecycle management solutions for law firms and corporations worldwide. It offers document creation, comparison, collaboration, and cleansing software solutions that manage documents throughout their lifecycle. "
seller: Axxiem Web Solutions
AxxiTRIALS developed by Axxiem is a web-based clinical trials communication portal. AxxiTRIALS provides a simple and secure way to efficiently distribute and track time-sensitive documents and training materials to users around the world.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/25/2008 via BusinessWire

Bio-Imaging Technologies, Inc., acquired Phoenix Data Systems Inc.

synopsis: Bio-Imaging Technologies, Inc. it has acquired privately held Phoenix Data Systems, Inc., a leading global clinical data services provider of electronic data capture services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries.
buyer: Bio-Imaging Technologies, Inc.
BioClinica is a global clinical trials service organization, providing medical image management and eClinical services. This includes electronic data capture and clinical data management solutions to pharmaceutical, biotechnology and medical device companies and other organizations. "
target: Phoenix Data Systems Inc.
Phoenix Data Systems delivers Full Service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management services that give clinical data managers improved control to run well-managed studies.
price ($mm)[EV]
$19 [$18]
rev ($mm)
$12
EBITDA ($mm)
$1
EV / rev
1.8x
EV / EBITDA
15.4x
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,061.43)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via PR Newswire

BioClinica, Inc., acquired Clinverse, Inc.

synopsis: Bioclinica, Inc., a specialty trials services and technology provider, announced it has acquired Clinverse, Inc. Clinverse automates and manages the entire financial lifecycle of global clinical trials for contract research organizations and pharmaceutical companies. Its suite of products pays clinical trial sites, vendors and their subjects.
buyer: BioClinica, Inc.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized into three business segments to deliver focused service and multifaceted technologies. "
target: Clinverse, Inc.
Clinverse, Inc. architected the industry's first automated financial management technology solution for clinical trials. Their solution standardizes clinical trial financial management for millions of financial transactions across the globe, including clinical site payments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2015 via PR Web

Aris Global LLC, acquired Medsight Solutions Inc.

synopsis: ArisGlobal®, a leading provider of Cloud solutions to life sciences companies, is pleased to announce that it has acquired Medsight Solutions, including the revolutionary integrated risk management solution, Medsight Sapphire (now known as ArisGlobal agBalance™).
buyer: Aris Global LLC
For more than 20 years, ArisGlobal has led in the development of innovative software solutions for pharmacovigilance & safety, regulatory affairs, clinical research and medical information. "
target: Medsight Solutions Inc.
Medsight Solutions Inc. is a life sciences solutions and professional services company with specialties in Clinical trial optimization, Benefit-risk assessment and Compliance monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2014 via Company Press Release

ERT, acquired eClinical Insights, Inc.

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights (eCI), an innovative provider of cloud-based clinical trials management software.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target: eClinical Insights, Inc.
eClinical Insights® is a leading-edge provider of cloud-based clinical software that provides clinical research professionals with the strategic visibility to make rapid, data-driven decisions to positively impact the performance and cost of their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/24/2017 via BNC Analysis

ERT, acquired ImageIQ

synopsis: ERT - a provider of clinical trial services - announced the acquisition of ImageIQ, an imaging software and contract research organization and software developer for customized imaging and analysis.
buyer parent: Nordic Capital
buyer: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions. "
target: ImageIQ
ImageIQ is an imaging software and contract research organization and software developer for customized imaging and analysis.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/8/2016 via Company Press Release

ERT, acquired Exco InTouch, Ltd.

synopsis: ERT announced the acquisition of Exco InTouch, a leading provider of patient engagement, data capture and digital health solutions. The combined organization will provide the biopharmaceutical industry with the most advanced and comprehensive choice for electronic clinical outcome assessments (eCOA), patient engagement and digital health.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions. "
target: Exco InTouch, Ltd.
Exco InTouch is a leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers. Exco InTouch solutions provide simple, secure channels of communication; facilitating the collection of quality data and improving outcomes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
announced 2/27/2015 via PR Newswire

ERT, will acquire PHT Corporation

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation, the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced that they have signed a definitive agreement under which ERT will acquire PHT.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target parent: Boston Millennia Partners
target: PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2014 via Company Press Release

ERT, acquired eClinical Insights, Inc.

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights (eCI), an innovative provider of cloud-based clinical trials management software.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target: eClinical Insights, Inc.
eClinical Insights® is a leading-edge provider of cloud-based clinical software that provides clinical research professionals with the strategic visibility to make rapid, data-driven decisions to positively impact the performance and cost of their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2012 via PR Newswire

ERT, acquired invivodata, Inc.

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CROs), announced the acquisition of invivodata, Inc, a leading provider of electronic Patient Reported Outcomes (ePRO) solutions and Consulting services, based in Pittsburgh, PA.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives. "
target: invivodata, Inc.
invivodata is a fully-integrated Clinical Outcome Assessments organization delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 6/24/2009 via PR Newswire

OmniComm Systems, Inc., purchased EDC Solutions from eResearch Technology, Inc.

synopsis: OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, has acquired the EDC business of eResearchTechnology, Inc., a global provider of technology and services that enable life science industries worldwide to collect, interpret, and distribute cardiac safety and clinical data.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. "
seller: eResearch Technology, Inc.
eResearchTechnology, Inc. (eRT) is a provider of technology-based products and services that enable the pharmaceutical, biotechnological, medical device, and contract resource companies to collect, interpret, and distribute cardiac safety and clinical data more efficiently.
price ($mm)[EV]
$2.02 [$0.87]
rev ($mm)
$6
EBITDA ($mm)
EV / rev
0.1x
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 8/2/2004 via BusinessWire

Apogent Technologies, Inc. merged with Fisher Scientific International Inc.,

synopsis: Fisher Scientific International Inc. (NYSE: FSH) today completed its approximately $4.0 billion merger with Apogent Technologies Inc. (formerly trading as NYSE: AOT), providing Fisher Scientific with a $1.1 billion footprint in the high-growth life-science market.
buyer parent: Thomas H. Lee Partners, L.P.
buyer: Fisher Scientific International Inc.
Fisher Scientific International, Inc. provides products and services to the scientific research and clinical laboratory markets. It operates in three segments: Scientific Products and Services, Healthcare Products and Services, and Laboratory Workstations. The Scientific Products and Services segmen"
target: Apogent Technologies, Inc.
Apogent Technologies Inc. is a developer and manufacturer of value-added products for the clinical and research markets. Over 80% of the Company's products are consumables. Apogent's operating subsidiaries manufacture most of their products in approximately 80 facilities worldwide. The Company's cu
price ($mm)
$3,991
rev ($mm)
$1,118
EBITDA ($mm)
$313
EV / rev
3.6x
EV / EBITDA
12.7x
announced 1/22/2020 via PR Newswire

Clarivate Analytics, will acquire Decision Resources Group

synopsis: Clarivate Analytics plc, a global leader in providing trusted insights and analytics, will acquire Decision Resources Group ("DRG"), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of global business conglomerate Piramal Group.
buyer: Clarivate Analytics (:$964.58)
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management. "
target parent: Piramal Group
target: Decision Resources Group
Decision Resources Group (DRG) is uniquely positioned to help healthcare businesses improve the lives of patients around the world by creating patient-centric commercial strategies that drive better outcomes and better access.
price ($mm)
$950
rev ($mm)
$207
EBITDA ($mm)
$48
EV / rev
4.6x
EV / EBITDA
20.0x
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
announced 1/13/2020 via GlobeNewswire

TelaDoc, Inc., will acquire InTouch Health

synopsis: Teladoc Health, Inc., the global leader in virtual care, will acquire InTouch Health, the leading provider of enterprise telehealth solutions for hospitals and health systems. This acquisition positions Teladoc Health as the partner of choice for health systems seeking a single solution for their entire virtual care strategy.
buyer: TelaDoc, Inc. (TDOC:$716.29)
Teladoc Health is transforming the healthcare experience with a focus on high quality, lower costs, and improved outcomes. Telehealth Satisfaction Study, the integrated services from Teladoc Health include telehealth, expert medical services, AI and analytics, and licensable platform services. "
target parent: Galen Partners
target: InTouch Health
InTouch Health is a telehealth services company that offers healthcare providers a reliable, dedicated cloud-based network and virtual care solutions to efficiently deliver care for a broad array of use cases and healthcare environments.
price ($mm)
$600
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/27/2009 via Reuters

The Carlyle Group, will acquire Broadleaf Co., Ltd.

synopsis: Private equity firm The Carlyle Group announced that it has agreed to purchase Broadleaf Co, a Japanese maker of software for car maintenance facilities. This is the first buyout for Carlyle in Japan since it bought LCD glass maker AvanStrate Inc.
buyer: The Carlyle Group (CG:$1,614.20)
The Carlyle Group is a private global investment firm that originates, structures and acts as lead equity investor in management-led buyouts, strategic minority equity investments, equity private placements, consolidations and buildups, and growth capital financings. "
target parent: Olympus Corporation
target: Broadleaf Co., Ltd.
Broadleaf Co. is involved in the development, sale, and support of various software packages for the automotive industry, including the Super Frontman automobile maintenance system, administrative system packages for inventory control, customer control, and estimate/sales/billing control.
price ($mm)
$212
rev ($mm)
$181
EBITDA ($mm)
EV / rev
1.2x
EV / EBITDA
closed 12/11/2019 via PR Newswire

Corrona, Inc., acquired HealthiVibe LLC

synopsis: Corrona, LLC, a leading provider of real-world observational and syndicated registry data, announced that it has acquired HealthiVibe, LLC, a leading patient experience company. HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle.
buyer parent: Great Point Partners
buyer: Corrona, Inc.
Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. "
target: HealthiVibe LLC
HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle. They leverage models and online analytic platforms to provide tools to optimize clinical trials and enhance product commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/26/2020 via PR Newswire

Arsenal Capital Partners, acquired BresMed Health Solutions Ltd

synopsis: Arsenal Capital Partners, a leading private equity firm investing in healthcare and specialty industrials companies, announced the acquisition of BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry.
buyer: Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle‐market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, and completed more than 45 platform investments. "
target: BresMed Health Solutions Ltd
BresMed is a health economic and outcomes research consultancy that provides health economic solutions to the global pharmaceutical industry. Established in 2006, BresMed has more than 150 staff across offices in the U.K., Ireland, the Netherlands, the U.S., and India.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/5/2020 via GlobeNewswire

Livongo will be merged with TelaDoc, Inc.,

synopsis: Teladoc Health, the global leader in virtual care, and Livongo, the leading Applied Health Signals company, have entered into a definitive merger agreement. The combination of Teladoc Health and Livongo will create a global leader in consumer centered virtual care. The combined company will operate under the Teladoc Health brand.
buyer: TelaDoc, Inc. (TDOC:$716.29)
Teladoc Health is recognized as the world leader in virtual care. They deliver millions of medical visits across 175 countries annually through the Teladoc Health Medical Group, enabling millions of patient and provider touchpoints for hospitals, health systems, and physician practices globally. "
target: Livongo (LVGO:$257.96)
Livongo empowers people with chronic conditions to live better and healthier lives. Using its AI+AI engine, Livongo aggregates and interprets health data and information to create actionable, personalized, and timely health signals delivered to Livongo Members exactly when and where they need them.
price ($mm)[EV]
$16,988 [$16,567]
rev ($mm)
$258
EBITDA ($mm)
EV / rev
70.8x
EV / EBITDA
announced 6/3/2020 via BusinessWire

BreathResearch will be merged with AireHealth,

synopsis: AireHealth Inc., a company that offers affordable treatments, symptom tracking and early detection of respiratory conditions, has reached a merger agreement with BreathResearch, a respiratory healthcare company that detects increasing declines in respiratory health status.
buyer: AireHealth
AireHealth offers affordable treatments, symptom tracking and early detection of respiratory conditions. The company provides monitored drug delivery via its FDA cleared Class 2 portable nebulizer, designed to deliver medicine directly to a patient’s lungs where it is most effective. "
target: BreathResearch
BreathResearch is an innovative healthcare company that offers a solution that converts the air waves from breathing into sound waves producing new respiratory analytics to improve health, fitness and performance.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/22/2005 via BNC Analysis

Clinical Data, Inc., will acquire Genaissance Pharmaceuticals, Inc.

synopsis: Clinical Data Inc. announced Tuesday that it will acquire Genaissance Pharmaceuticals in an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 percent of the combined company when the deal closes sometime in the fourth quarter.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Genaissance Pharmaceuticals, Inc.
Genaissance is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and Pharmacogenomic support services to the pharmaceutical industr
price ($mm)
$56
rev ($mm)
$21
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 1/9/2020 via BusinessWire

Riverside Insights, acquired ImPACT Concussion Management

synopsis: Riverside Insights, a provider of educational and clinical assessments and a portfolio company of Alpine Investors, has acquired ImPACT Applications, Inc., a leading provider of research-backed concussion assessments. ImPACT Applications offers the only FDA-cleared neurocognitive evaluation aid with concussion specific indications for ages 12-59.
buyer parent: Alpine Investors, LP
buyer: Riverside Insights
Riverside is a provider of educational and clinical assessments that play a key role in helping individuals elevate their learning potential by providing accurate and reliable data. Riverside is comprised of several iconic, leading brands such as Woodcock-Johnson, the Iowa Assessments, and CogAT. "
target: ImPACT Concussion Management
ImPACT Applications, Inc. is the maker of ImPACT, ImPACT Pediatric, and ImPACT Quick Test, all FDA cleared Class I & II medical devices and software solutions that assist in the screening, assessment, and management of concussion.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like eClinical Insights, Inc.


read more

eClinical Insights, Inc.

Comprehend Systems, Inc.

eResearch Technology, Inc.

etrials, Inc.

Medimix International

Relay Technology Management

Axxiem Web Solutions

Phoenix Data Systems Inc.

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

Sylogent

Parallel 6

SecureConsent

Clinverse, Inc.

Medsight Solutions Inc.

read more

eClinical Insights, Inc.

read more

ImageIQ

Exco InTouch, Ltd.

ERT

PHT Corporation

eClinical Insights, Inc.

invivodata, Inc.

ERT

eResearch Technology, Inc.

read more

ERT

ERT

Apogent Technologies, Inc.

Decision Resources Group

Abacus International

Decision Resources Group

InTouch Health

Broadleaf Co., Ltd.

HealthiVibe LLC

CenterWatch, Inc.

CenterWatch, Inc.

CenterWatch, Inc.

Advarra

BresMed Health Solutions Ltd

Context Matters

Livongo

BreathResearch

AAIPharma Services

Genaissance Pharmaceuticals, Inc.

ImPACT Concussion Management

Geography
Matching Companies
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: ENXTPA:DIM
 
 
 
 
 
 
 
 
Sartorius AG
Sartorius AG
Sartorius is a international pharmaceutical and laboratory equipment supplier. With their innovative products and services, they are helping their customers across the entire globe to implement their complex and quality-critical biomanufacturing and laboratory processes reliably and economically.
year
2016
rev ($mm)
$1,121.72
EBITDA ($mm)
$299.20
EBIT ($mm)
$257.20
Net Income ($mm)
$163.92
Employees
4590
  • drill down
  • watch
Ticker: ENXTPA:BIM
 
 
 
 
 
 
 
 
bioMérieux S.A.
bioMérieux S.A.
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety.
year
2015
rev ($mm)
$1,996.55
EBITDA ($mm)
$404.73
EBIT ($mm)
$278.41
Net Income ($mm)
$155.44
Employees
9258
  • drill down
  • watch
Ticker: XTRA:SBS
 
 
 
 
 
 
 
 
Stratec SE
Stratec SE
STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications.
year
2019
rev ($mm)
$240.89
EBITDA ($mm)
$38.57
EBIT ($mm)
$21.94
Net Income ($mm)
$15.69
Employees
1223
  • drill down
  • watch
Ticker: ABT
 
 
 
 
 
 
 
 
Abbott Laboratories
Abbott Laboratories
Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
year
2009
rev ($mm)
$30,764.71
EBITDA ($mm)
$8,220.25
EBIT ($mm)
$6,130.74
Net Income ($mm)
$5,745.84
Employees
73000
  • drill down
  • watch
Ticker: BDX
 
 
 
 
 
 
 
 
Becton, Dickinson and Company
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a leading medical technology company. BD’s innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.
year
2012
rev ($mm)
$7,708.38
EBITDA ($mm)
$1,970.62
EBIT ($mm)
$1,577.89
Net Income ($mm)
$1,169.93
Employees
  • drill down
  • watch
Ticker: SYK
 
 
 
 
 
 
 
 
Stryker Corporation
Stryker Corporation
Stryker Corporation is one of the world's leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties.
year
2016
rev ($mm)
$10,062.00
EBITDA ($mm)
$2,717.00
EBIT ($mm)
$2,312.00
Net Income ($mm)
$1,617.00
Employees
27000
  • drill down
  • watch
Ticker: CAH
 
 
 
 
 
 
 
 
Cardinal Health, Inc.
Cardinal Health, Inc.
Cardinal Health, Inc. improves the cost-effectiveness of the health care industry. Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability.
year
2018
rev ($mm)
$141,935.00
EBITDA ($mm)
$2,870.00
EBIT ($mm)
$1,860.00
Net Income ($mm)
Employees
50200
  • drill down
  • watch
Ticker: FMS
 
 
 
 
 
 
 
 
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA
As a vertically integrated company, we offer products and services for the entire dialysis value chain. The highest medical standards are our benchmark.
year
2009
rev ($mm)
$11,247.48
EBITDA ($mm)
$2,212.68
EBIT ($mm)
$1,755.60
Net Income ($mm)
$891.14
Employees
72812
  • drill down
  • watch
Ticker: COV
 
 
 
 
 
 
 
 
Covidien
Covidien
Tyco Healthcare became Covidien and began independently trading on the New York and Bermuda Stock Exchanges on July 2, 2007, marking its debut as an independent diversified global healthcare products company.
year
2010
rev ($mm)
$10,429.00
EBITDA ($mm)
$2,628.00
EBIT ($mm)
$2,139.00
Net Income ($mm)
$1,632.00
Employees
41500
  • drill down
  • watch
Ticker: FAGR
 
 
 
 
 
 
 
 
Fagron
Fagron
Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries.
year
2014
rev ($mm)
$473.30
EBITDA ($mm)
$113.50
EBIT ($mm)
$96.32
Net Income ($mm)
$17.17
Employees
1902
  • drill down
  • watch
Ticker: SPA
 
 
 
 
 
 
 
 
Sparton Corporation
Sparton Corporation
Sparton Corporation, now in its 115th year, is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, field service, and refurbishment.
year
2014
rev ($mm)
$338.86
EBITDA ($mm)
$32.07
EBIT ($mm)
$23.21
Net Income ($mm)
$10.89
Employees
1385
  • drill down
  • watch
Ticker: SGN
 
 
 
 
 
 
 
 
Signalife, Inc.
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring.
year
2007
rev ($mm)
EBITDA ($mm)
($14.36)
EBIT ($mm)
($14.46)
Net Income ($mm)
Employees
15
  • drill down
  • watch
Ticker: HAE
 
 
 
 
 
 
 
 
Haemonetics Corporation
Haemonetics Corporation
Haemonetics is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions. Their technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.
year
2020
rev ($mm)
$988.48
EBITDA ($mm)
$266.02
EBIT ($mm)
$173.83
Net Income ($mm)
$76.53
Employees
3004
  • drill down
  • watch
Ticker: BABY
 
 
 
 
 
 
 
 
Natus Medical, Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment and neurological dysfunction.
year
2014
rev ($mm)
$352.46
EBITDA ($mm)
$64.99
EBIT ($mm)
$54.44
Net Income ($mm)
$30.91
Employees
943
  • drill down
  • watch
Ticker: MDT
 
 
 
 
 
 
 
 
Medtronic, Inc.
Medtronic, Inc.
Medtronic develops and manufactures a wide range of products and therapies with emphasis on providing a complete continuum of care to diagnose, prevent and monitor chronic conditions.
year
2020
rev ($mm)
$31,062.00
EBITDA ($mm)
$9,558.00
EBIT ($mm)
$7,097.00
Net Income ($mm)
$5,408.00
Employees
90000
  • drill down
  • watch